Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Hydroxychloroquine. Photo: George Frey/AFP via Getty Images

Editor’s note: The study referenced in this story has been retracted by the medical journal The Lancet due to questions on the veracity of its primary data sources. Read more here.

Coronavirus patients who took hydroxychloroquine or its related drug chloroquine were more likely to die or develop an irregular heart rhythm that can lead to sudden cardiac death, compared to those who did nothing, a retrospective review published in The Lancet shows.

Why it matters: Despite warnings from the Food and Drug Administration, President Trump has insisted the anti-malarial drug as a "game-changer" and admitted he has taken it as a preventative even though the drug is unproven.

The big picture: The medical journal's review consisted of 96,000 hospitalized patients diagnosed with the coronavirus in six continents, the largest analysis of medical records on the drug, between Dec. 20, 2019, and April 14, 2020.

  • About 15,000 of the 96,000 patients were treated with hydroxychloroquine or chloroquine alone, or combined with an antibiotic known as a macrolide.

The findings: Those given the drug alone had a 34% increased risk of dying and a 137% increased risk of heart arrhythmias.

  • Those who took the drug paired with an antibiotic had a 45% increased risk of death and a 411% risk of heart arrhythmias. This combination is one President Trump has been encouraging.

The mean age of patients was 54 years old and 53% were men.

  • Those excluded were those on mechanical ventilators or who received remdesivir, an antiviral drug made by Gilead Sciences.

The bottom line: The FDA has adamantly warned against taking hydroxychloroquine or chloroquine because of the risk of heart complications and unproven claims it prevents COVID-19 infections.

Go deeper: Stunned Fox News host reacts to Trump taking hydroxychloroquine

Go deeper

Updated 22 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Vaccines: Biden to get booster shot on camera — Pfizer vaccine safe, effective in children, company says — The booster vaccine discussion is far from over.
  2. Health: Study: Pandemic cut U.S. life expectancy by more than 9 million years — U.S. death toll surpasses 1918 flu fatalities — Chicago has highest case rates in city worker neighborhoods.
  3. Politics: Biden to push vaccine-sharing at UN, but boosters at home — Rep. Tim Ryan tests positive — Biden administration to lift travel ban for fully vaccinated international travelers.
  4. Education: D.C. schools to require teachers, staff to receive vaccine without testing option — More schools using "test-to-stay" strategy to minimize quarantines.
  5. Variant tracker: Where different strains are spreading.
Ben Geman, author of Generate
1 hour ago - Energy & Environment

The road to COP26 gets slightly easier

Illustration: Annelise Capossela/Axios

The bad diplomatic vibes heading into the critical United Nations climate summit in Glasgow, Scotland, might be improving slightly.

Catch up fast: Chinese President Xi Jinping yesterday pledged to end overseas finance for building new coal-fired power plants and boost support for clean energy in developing nations.

Narrowing the employee divide

Illustration: Shoshana Gordon/Axios

Companies are narrowing the blue- and white-collar experience as they're forced to adapt to a worker-led market.

Driving the news: Basic office tools and concepts like corporate communications and schedule flexibility are migrating to frontline operations through investments in technology.